IP Library Granted Patent US 7,682,626
Granted Patent B2
US 7,682,626 · App. 10/772,502 · Granted Mar 23, 2010

Polyvinylethers for delivery of polynucleotides to mammalian cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,682,626
App. No.
10/772,502
Granted
Mar 23, 2010
Kind
B2
Abstract

A class of polymers for delivery of polynucleotides to cells in described. More specifically, amphiphilic polyvinylethers and compositions containing amphiphilic polyvinylethers are described.

Claims (20)

1. A composition for delivery of a polynucleotide to a cell comprising:

the polynucleotide and a cationic polyvinylether random copolymer, wherein the polyvinylether random copolymer comprises cationic monomeric units and alkyl or aryl monomeric units and is capable of lysing red blood cells.

2. The composition of claim 1 wherein the polynucleotide is associated with the polyvinylether via an electrostatic interaction.

3. The composition of claim 1 wherein the polynucleotide is associated with the polyvinylether via labile covalent linkage.

4. The composition of claim 3 wherein the polynucleotide is associated with the polyvinylether via labile maleamate covalent linkage.

5. The composition of claim 1 wherein the polynucleotide is selected from the list consisting of: DNA, plasmid DNA, linear DNA, dsDNA, ssDNA, RNA, expression cassette,

antisense oligonucleotide, siRNA, microRNA, RNA expression cassette, ribozyme, dsRNA, and synthetic polynucleotides.

6. The composition of claim 5 wherein the polynucleotide expresses a protein.

7. The composition of claim 5 wherein the polynucleotide expresses an RNA.

8. The composition of claim 5 wherein the polynucleotide inhibits expression of a gene in the cell.

9. The composition of claim 1 wherein amines on the polyvinylether random copolymer are reversibly modified to carboxyls to convert the polyvinylether random copolymer to a labile polyanion.

10. The composition of claim 9 wherein the polynucleotide is covalently linked to the reversibly modified polyvinylether random copolymer via a labile maleamate bond.

11. The composition of claim 1 wherein the cationic monomeric units consist of amine-containing monomeric units.

12. The composition of claim 1 wherein the polyvinylether random copolymer comprises cationic monomeric units and at least two classes of alkyl or aryl monomeric units.

13. The composition of claim 12 wherein the cationic monomeric units consist of amine-containing monomeric units.

14. The composition of claim 13 wherein the alkyl monomeric units contain alkyl groups selected from the group consisting of: ethyl, propyl, butyl, dodecyl, and octadecyl.

15. A composition for delivery of a polynucleotide to a cell comprising:

the polynucleotide, a cationic polymer, and an anionic reversibly modified polyvinylether random copolymer wherein the anionic reversibly modified polyvinylether random copolymer comprises hydrophobic monomeric units and 2-propionic-3-methylmaleic anhydride modified amine-containing monomeric units wherein:

a) the modified polyvinylether random copolymer is not membrane active and

b) cleavage of the 2-propionic-3-methylmaleic anhydride groups from the amine-containing monomeric units results in an unmodified polyvinylether random copolymer that is membrane active and capable of lysing red blood cells.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2024
From: ARROWHEAD MADISON INC.
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068227/0904 →
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
CHANGE OF NAME Recorded Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →